{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:04:13Z","timestamp":1789542253328,"version":"build-2803163510"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"Importance<\/jats:title>Acute promyelocytic leukemia (APL) is an acute illness that presents with cytopenia, infections, and disseminated intravascular coagulation. Achieving remission has been shown to make a major difference in patient outcomes; however, early death rates in the first month have been as high as 30% due to acute presentation, comorbidities, the rarity of APL, and clinician inexperience.<\/jats:p><\/jats:sec>Objective<\/jats:title>To develop treatment strategies that would decrease estimated 1-month mortality from 30% to below 15%.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this nonrandomized clinical trial, a treatment algorithm that focused on supportive care was used to prevent early death in patients with APL treated at academic and community health centers between August 2017 and July 2021. Because of the rarity of the disease, expert support was available 24\/7 from 7 designated APL experts at 6 participating academic lead centers, and included an additional 293 community centers. When a patient presented with APL, an expert was contacted and a consensus treatment plan was developed using the algorithm and expert suggestions. There were no exclusion criteria and all patients with a confirmed diagnosis of APL regardless of age or comorbid conditions were enrolled. Expert support was provided throughout induction. Initial data analysis was conducted May 2023.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>One-month mortality; additional objectives were to compare outcomes in academic and community centers and assess 1-year and overall survival.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 201 patients were enrolled from 43 centers; 62 at lead centers and 139 from 37 community centers. The median age was 53 years (range, 18-91 years), with 72 patients (35.8%) who were aged 60 years or older; 105 patients (52.2%) were male. Fifty-two patients (26.4%) were diagnosed with high-risk APL. The 1-month mortality rate was 6 deaths of 201 patients (3.0%; 95% CI, 1.1%-6.4%) after adjusting for 1 interim analysis. In a secondary analysis using the Kaplan-Meier method, the 1-month overall survival (OS) rate was 97.0% (95% CI, 93.5%-98.6%) and the 1-year OS rate was 94.5% (95% CI, 90.3%-96.9%).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this nonrandomized clinical trial, use of an algorithm combined with expert support resulted in a dramatic decrease in early death in academic and community centers. Population-wide survival improved in this highly curable disease, which suggests that implementing an accessible support system with APL experts for comanagement is the most logical next step.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03253848<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.7033","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:33:13Z","timestamp":1740673993000},"page":"400","source":"Crossref","is-referenced-by-count":10,"title":["Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality"],"prefix":"10.1001","volume":"11","author":[{"given":"Anand P.","family":"Jillella","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Y.","family":"Law","sequence":"additional","affiliation":[{"name":"Roseville Medical Center, Roseville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Locke J.","family":"Bryan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Abou Zahr","sequence":"additional","affiliation":[{"name":"Sanford Roger Maris Cancer Center, Fargo, North Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J. L.","family":"Vadakara","sequence":"additional","affiliation":[{"name":"Geisinger Medical Center, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Qamar","sequence":"additional","affiliation":[{"name":"Advocate Aurora Health Care, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Bergan","sequence":"additional","affiliation":[{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisch","sequence":"additional","affiliation":[{"name":"Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth C.","family":"Carlos","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"coi240083r1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"coi240083r2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"coi240083r3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"issue":"10","key":"coi240083r4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.10874","article-title":"Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines.","volume":"92","author":"J\u00e1como","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"coi240083r5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"coi240083r6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"issue":"23","key":"coi240083r7","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"coi240083r8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia.","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"issue":"15","key":"coi240083r9","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1200\/jco.2012.30.15_suppl.6573","article-title":"A simple but effective model to decrease early deaths in acute promyelocytic leukemia (APL).","volume":"30","author":"Jillella","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi240083r11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.12931","article-title":"Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study.","volume":"166","author":"Paulson","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"coi240083r12","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.clml.2018.11.004","article-title":"Real-life outcomes on acute promyelocytic leukemia in Brazil\u2014early deaths are still a problem.","volume":"19","author":"Silva","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"coi240083r13","first-page":"82","article-title":"Improved outcome in early induction deaths in patients with acute promyelocytic leukemia after therapeutic and supportive interventions: a follow up study of seven-years\u2019 experience at a tertiary care center.","volume":"10","author":"Shaikh","year":"2020","journal-title":"Am J Blood Res"},{"key":"coi240083r14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.895777","article-title":"Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia.","volume":"12","author":"Wen","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"coi240083r15","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1016\/j.clml.2022.11.005","article-title":"Improvement of early death in acute promyelocytic leukemia: a population-based analysis.","volume":"23","author":"Li","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"coi240083r16","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.4081\/hr.2019.7896","article-title":"Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA.","volume":"11","author":"Bolds","year":"2019","journal-title":"Hematol Rep"},{"issue":"4","key":"coi240083r17","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1200\/OP.20.00395","article-title":"Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia.","volume":"17","author":"Jillella","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"coi240083r18","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"issue":"15","key":"coi240083r19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"6","key":"coi240083r20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms.","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"coi240083r21","first-page":"5017","article-title":"Weight gain during induction therapy of acute promyelocytic leukemia patients: a preventable problem.","volume":"130","author":"Kota","year":"2017","journal-title":"Blood"},{"issue":"18","key":"coi240083r22","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/cncr.32196","article-title":"Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.","volume":"125","author":"Chamoun","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"coi240083r23","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi240083r24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"5","key":"coi240083r25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00277-023-05154-0","article-title":"Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States.","volume":"102","author":"Sharma","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"coi240083r26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/OP.20.00600","article-title":"State of physician and pharmacist oncology workforce in the United States in 2019.","volume":"17","author":"Shih","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"coi240083r27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00277-012-1597-9","article-title":"Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.","volume":"92","author":"Lengfelder","year":"2013","journal-title":"Ann Hematol"},{"issue":"2","key":"coi240083r28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.24230","article-title":"Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: a pooled analysis from four CALGB (alliance) clinical trials.","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol"},{"issue":"11","key":"coi240083r29","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index.","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"coi240083r30","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1182\/blood.V122.21.1714.1714","article-title":"Acute promyelocytic leukemia in Canada: Poor outcomes in older patients remain.","volume":"122","author":"Seftel","year":"2013","journal-title":"Blood"},{"issue":"22","key":"coi240083r31","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood.V128.22.1622.1622","article-title":"A prospective multi-center trial shows reduction of early deaths (ED) and improved survival in elderly acute promyelocytic leukemia (APL) patients (>60 years). results of using a simplified treatment algorithm and expert support in Georgia, South Carolina and neighboring states.","volume":"128","author":"Kota","year":"2016","journal-title":"Blood"},{"issue":"12","key":"coi240083r32","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1182\/blood.V82.12.3560.3560","article-title":"Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg\/m2) in acute promyelocytic leukemia.","volume":"82","author":"Castaigne","year":"1993","journal-title":"Blood"},{"issue":"11","key":"coi240083r33","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2012-08-449918","article-title":"Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.","volume":"121","author":"Rego","year":"2013","journal-title":"Blood"},{"issue":"23","key":"coi240083r34","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers.","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"key":"coi240083r10","unstructured":"Jillella? A, Lane? B, Rosshandler? Y, . A simple and effective strategy to decrease early deaths in acute promyelocytic leukemia using a streamlined set of guidelines paired with expert support.? Haematologica. 2014;99(suppl_1):298. Accessed June 27, 2024. https:\/\/haematologica.org\/article\/view\/7071"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2830628\/jamaoncology_jillella_2025_oi_240083_1744202987.56508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:01:47Z","timestamp":1744902107000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2830628"}},"subtitle":["The ECOG-ACRIN EA9131 Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.7033","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}